Glucotrack publishes peer-reviewed study showing CBGM accuracy MARD 6.8% over 240 days in ovine model

Glucotrack, Inc.

Study in Journal of Diabetes Research shows weighted average MARD of 6.8% across 79 IV glucose tolerance tests in ovine model.
34 devices implanted in 17 sheep; no device-related adverse events observed over up to 240 days.
Results support path to IDE submission with FDA for further clinical development toward commercialization.
Prior first-in-human study demonstrated MARD of 7.7% with 99% data capture and no serious adverse events.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.